Natera, Inc. (NASDAQ:NTRA) CFO Sells $233,416.54 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,442 shares of Natera stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $161.87, for a total transaction of $233,416.54. Following the transaction, the chief financial officer now owns 108,032 shares of the company’s stock, valued at $17,487,139.84. The trade was a 1.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total value of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Trading Up 4.8 %

NTRA opened at $176.27 on Friday. Natera, Inc. has a 12-month low of $64.74 and a 12-month high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company’s 50 day moving average is $166.70 and its 200 day moving average is $137.70.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.95) EPS. As a group, equities analysts expect that Natera, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the topic of a number of analyst reports. Piper Sandler upped their price target on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. The Goldman Sachs Group raised their price target on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday. Sanford C. Bernstein upped their price objective on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, January 10th. Finally, Craig Hallum lifted their target price on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $165.88.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP grew its stake in shares of Natera by 205.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after acquiring an additional 1,883,481 shares during the period. PointState Capital LP boosted its position in shares of Natera by 112.0% in the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock worth $99,343,000 after purchasing an additional 413,468 shares during the period. Franklin Resources Inc. increased its stake in shares of Natera by 42.6% in the third quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company’s stock worth $144,958,000 after purchasing an additional 328,375 shares in the last quarter. ARK Investment Management LLC raised its position in shares of Natera by 65.6% during the 3rd quarter. ARK Investment Management LLC now owns 687,703 shares of the medical research company’s stock valued at $87,304,000 after purchasing an additional 272,361 shares during the period. Finally, Maverick Capital Ltd. lifted its stake in shares of Natera by 25.2% during the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock valued at $170,119,000 after buying an additional 269,706 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.